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Abstract 
Word count: 247 (max 250) 
 
Objectives 
Whilst cognitive impairment is frequently reported in HIV-positive individuals and has 
historically been associated with poorer functional outcomes, the associations between 
cognitive impairment and patient-reported outcome measures (PROMs) in contemporary 
cohorts are unclear. 
 
Methods 
We tested cognitive function using a computerised battery (CogState™) in 290 HIV-positive 
and 97 HIV-negative individuals aged ≥50 participating in the POPPY Study. Participants 
completed questionnaires detailing physical and mental health (SF-36), cognitive function 
(EACS questions), activities of daily living (Lawton IADL), depression (PHQ-9, CES-D), falls and 
sexual desire. 
 
Cognitive impairment was defined using the Frascati criteria, global deficit score (GDS) and 
multivariate normative comparison (MNC). In the HIV-positive group, classification 
performance of the different definitions of cognitive impairment and dichotomised 
questionnaire results were calculated. 
 
Results 
Prevalence of cognitive impairment in the HIV-positive group was 34.5% (GDS), 30.0% 
(Frascati) and 22.1% (MNC) with only 2% diagnosed with HIV-associated dementia. In 
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general, the associations between cognitive impairment and PROMs were weak regardless 
of the definition used: mean c-statistics were 0.543 (GDS), 0.530 (MNC) and 0.519 (Frascati). 
Associations were similar using the global T-score to define cognitive impairment. Summary 
health scores (SF-36) were lower, but only significantly so for those with cognitive 
impairment identified using MNC, for both mental health (61.4 vs. 75.8, p=0.03) and 
physical health (60.9 vs. 75.0, p=0.03).  
 
Conclusion 
The associations between cognitive impairment and PROMs were weak, possibly because 
impairment was mild and therefore largely asymptomatic. Further work is needed to 
elucidate the clinical implications of cognitive impairment in HIV-disease. 
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Introduction 
Despite the development of virologically effective combination antiretroviral therapy 
(cART), cognitive impairment remains frequently reported in HIV-positive individuals with 
several different diagnostic classification systems currently in use (1). The implicit 
assumption is that those with cognitive impairment are more likely to have a higher 
frequency of mental and physical complaints as part of a general syndrome of ill health. 
Whilst severe cognitive impairment has previously been associated with impairment of 
objective measures of everyday functioning, such reports were derived in patient 
populations with lower CD4+ lymphocyte cell counts than is typically seen in the current era, 
and in whom cART regimens would now be considered  suboptimal (2,3). Additionally, 
whilst associations with cognitive impairment and patient related outcomes may be 
statistically significant, the clinical significance of the associations seen are unclear. We 
aimed to test the hypothesis that cognitive impairment would be associated with other 
measures of mental and physical dysfunction in a contemporary cohort of HIV-positive 
individuals. 
 
Methods 
Participants 
Participants were prospectively enrolled into the Pharmacokinetic and Clinical Observations 
in People Over Fifty (POPPY) study (ClinicalTrials.gov Identifier: NCT01737047). This 
multicentre cohort study aims to investigate the effects of ageing and comorbidities on HIV-
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positive individuals in the UK and Ireland. Inclusion criteria were documented presence or 
absence of HIV-infection, self-defined white or Black-African ethnicity, age over 50 years at 
study entry and the ability to comprehend the study patient information leaflet. Additional 
inclusion criteria for the HIV-positive participants were probable route of HIV acquisition via 
sexual exposure (either by male-to-male exposure if white or by heterosexual exposure if 
white or Black-African). Considerable care was taken to recruit appropriate HIV-negative 
controls from sexual health clinics and using targeted community advertising and by 
frequency matching the controls to the HIV-positive participants by gender, ethnicity, sexual 
orientation and location (in or out London). 
 
The study was approved by the UK National Research Ethics Service (NRES; Fulham, London, 
UK, reference number 12/LO/1409). All participants provided written informed consent. 
 
Cognitive function testing 
All participants underwent cognitive function testing using a computerised battery 
(CogState™) covering six cognitive domains including visual learning, psychomotor function, 
visual attention, executive function, verbal learning and working memory (supplementary 
table 1). This has been shown to be a sensitive diagnostic tool for the assessment of HIV-
associated cognitive impairment and allows standardised assessment across sites  to be 
completed in a reasonable amount of time (4).  
 
Raw test scores were log-transformed or arcsine root–transformed where necessary (as per 
CogState analysis guidelines) and converted into demographically adjusted T-scores (mean: 
50, standard deviation: 10) using the HIV-negative control group as the reference 
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population accounting for age, level of education, gender and ethnicity as appropriate. This 
method was used as the CogState norms do not account for the range of age of participants 
in our study. Within each cognitive domain individual T-scores were averaged to calculate 
the domain T-score and across domains to calculate the global T-score. For all T-scores, 
higher scores indicate better cognitive function.  
 
Cognitive impairment was defined using published methods for HIV-associated 
neurocognitive disorder, commonly known as the ‘Frascati’ criteria (applied to domain T-
scores to minimise multiple testing) (5), the global deficit score (GDS) (6) and multivariate 
normative comparison (MNC) (7). We subdivided those with Frascati-defined impairment, 
using Lawton Instrumental Activities of Daily Living (IADL) (3), for descriptive purposes only 
to avoid circularity in assessing the relationship between objective cognitive impairment 
and subjective symptomology. We also tested a more stringent, combined definition of 
cognitive impairment whereby participants had to meet the Frascati, GDS and MNC criteria 
to be defined as impaired as well as using a global T-score cut-off of <45. This is equivalent 
to a change in z-score of 0.5 which is thought to represent a clinically significant difference 
in cognitive function and has been used as a primary outcome in clinical trials assessing 
interventions for the management of cognitive impairment in HIV-disease (8).  
 
Patient-reported outcome measures (PROMs) 
All participants answered the previously recommended cognitive complaints screening 
questions (9): ‘Do you experience frequent memory loss?’; ‘Do you feel that you are slower 
when reasoning, planning activities, or solving problems?’ and ‘Do you have difficulties 
paying attention?’. Participants also completed validated questionnaires detailing: physical 
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& mental health with the Short Form Health Survey (SF-36) (10); activities of daily living with 
the IADL (11) and depression with the Patient Depression Questionnaire (PHQ-9) (12) and 
the Centres for Epidemiologic Studies Depression scale (CES-D) (13). Additionally, falls and 
sexual desire were assessed by asking ‘over the past 28 days have you had any falls?’ and 
‘how often have you worried about minimal sexual desire during the last 4 weeks ?’ 
respectively. Outcomes were then dichotomised for further analysis (see supplementary 
data for details). 
 
Statistical analysis 
Demographic differences and comparisons of the prevalence of cognitive impairment 
between groups were assessed using the Chi-squared test and Wilcoxon rank-sum tests as 
appropriate. In the HIV-positive group, classification performance of the different 
definitions of cognitive impairment with dichotomised questionnaire results was assessed 
using the concordance (or ‘c’) statistic (equivalent to the area  under the receiver operating 
characteristic curve). This gives an indication of the ability of the different definitions of 
cognitive impairment to discriminate between those with and without symptoms based on 
the questionnaire data.  Concordance is typically considered reasonable when the c-statistic 
is >0.7 and strong when >0.8 (14). In addition, sensitivity and specificity were calculated. 
Optimal global T-score cut-offs were calculated for each PROM by maximising the c-statistic. 
Differences in physical and mental health between those with and without cognitive 
impairment were calculated using the Wilcoxon rank-sum tests. All analyses were 
performed using SAS v9.4 and R v3.2.1. Only p-values (two-sided) <0.05 were considered 
statistically significant. 
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Results 
Participants 
Of 387 participants enrolled between January 2013 and September 2014, 290 were HIV-
positive and 97 were matched HIV-negative controls (table 1). The HIV-positive group was 
typical of older patients in care in the UK with a median (IQR) age of 57 (53-62) years and 
CD4+ cell count of 610 (479-780) cells/µL; 80% of the HIV-positive group were receiving 
cART. HIV-positive and HIV-negative participants were well matched in terms of 
demographics such as age, ethnicity and level of educational attainment, however there 
was a slight preponderance of females in the HIV-negative control group. Recreational drug 
use was more frequent in the HIV-positive group.  
 
Cognitive function 
HIV-positive participants exhibited higher rates of cognitive impairment compared to the 
HIV-negative control group (table one). In general, cognitive impairment was mild with only 
8 (2.8%) and 6 (2.1%) HIV-positive participants fulfilling the Frascati definitions of mild 
neurocognitive disorder or HIV-associated dementia respectively. Cognitive impairment was 
not associated with recreational drug use in the last 6 months (p>0.2 for cognitive 
impairment defined with Frascati, GDS or MNC) or duration of known HIV-infection (p>0.4).  
Using a global T-score cut-off of 45 to define cognitive impairment the prevalence was 
31.0% vs. 16.5%, OR 2.28 (95% confidence interval 1.29 – 4.24, p<0.01) for the HIV-positive 
vs. HIV-negative groups respectively. 
 
 
Patient-reported outcome measures (PROMs) 
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Of the HIV-positive participants with complete data 79 (28.6%) reported frequent memory 
loss, 105 (38.2%) reasoning difficulties and 79 (28.9%) attention problems, 40 (14.3%) were 
not fully independent, 76 (28.9%) and 102 (39.1%) were depressed by PHQ-9 and CES-D 
scoring respectively, 50 (17.9%) reported falls in the last 28 days, and 125 (45.1%) reported 
minimal sexual desire over the preceding 4 weeks. 
 
In general, the associations between cognitive impairment and PROMs were weak 
regardless of the method of identification of cognitive impairment used (table 2): mean c-
statistics were 0.543 (GDS), 0.530 (MNC) and 0.519 (Frascati). Sensitivity analyses, excluding 
those with nervous system disorders did not significantly change associations. Using an 
alternative definition of cognitive impairment, based on a global T-score cut-off of <45, 
associations with PROMS were not dramatically improved (mean c-statistic 0.560). Even 
using the combined measure of cognitive impairment (14.1% of HIV-positive and 6.2% of 
HIV-negative individuals), the associations were weak (mean c-statistic 0.534). Concordance 
was optimised (mean c-statistic of 0.582) by varying the global T-score threshold by which 
cognitive impairment was defined (range 41.3-47.6) to maximise both sensitivity and 
specificity (table 2). The strongest associations between cognitive impairment and 
symptoms were consistently seen with memory loss and in general the weakest were with 
sexual desire.  
 
Summary health scores (SF-36) were lower in those with vs. without cognitive impairment, 
for both mental and physical health (supplementary figure 1) but only significantly so for 
cognitive impairment identified with MNC. 
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Discussion 
HIV-positive individuals exhibited poorer cognitive function when compared to an 
appropriate HIV-negative control group. As has been shown previously, the prevalence of 
cognitive impairment is sensitive to the method used (1). This presents a problem when 
trying to assess associations with other outcomes which is why we chose to study three 
commonly used definitions of cognitive impairment, their combination and the global T-
score with varying cut-offs. 
 
Regardless of the definition used, cognitive impairment correlated poorly with 
symptomatology. There are several possible explanations for our observations. Firstly, a lack 
of a ‘gold-standard’ method of diagnosing cognitive impairment may have limited our ability 
to make such observations. To mitigate against this, we have utilised several methods to 
define cognitive impairment in addition to trying different global T-score thresholds. 
Secondly, over-reporting of symptoms, whereby patients both with and without cognitive 
impairment report high rates of symptomatology makes finding associations challenging. 
Thirdly, the subjectivity of some questions regarding mental state (e.g. memory) makes it 
difficult to establish a clear relationship between subjective experience and objective 
measures of cognitive function. Similar reasons may explain the weak associations between 
cognitive impairment and other PROMs. Our findings are in contrast to previous studies 
which reported poorer functional outcomes (2,3), which may be explained by differences in 
populations. Previously published studies tended to have low levels of suppressive cART use 
and more severe cognitive impairment. Due to the higher frequency of prior AIDS events, 
participants were more likely to have accumulated disability. Therefore, it is likely that an 
increased severity of both cognitive impairment and symptomatology resulted in a stronger 
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association between the two. In contrast, our study population was comparatively well and 
the vast majority of cognitive impairment was mild with only 2% of the total HIV-positive 
population meeting the criteria of HIV-associated dementia. However, even using a 
stringent, combined definition of cognitive impairment, which only captures the most 
impaired, the associations with PROMS remained weak. This highlights the potential 
dichotomy between cognitive impairment and other PROMs. Longitudinal study is needed 
to assess prospectively the clinical impact of mild cognitive impairment. 
 
Limitations 
Although great effort was made to recruit a comparable control population, differences 
between the groups unrelated to HIV-infection may exist. As such, not all the differences in 
cognitive impairment we report here may be secondary to HIV-disease. To maximise 
recruitment and generalisability of our findings, exclusion criteria were kept to a minimum. 
As such, cognitive impairment could have been caused by degenerative neurological 
diseases other than HIV-disease. However, rates of neurological diagnoses did not differ 
significantly between the groups therefore rates of cognitive impairment should not be 
biased towards one group.  
 
Given our study is a ‘real-world’ sample and subjects were recruited prior to the publication 
of the INSIGHT START study not every HIV-positive individual was receiving suppressive 
antiretroviral therapy (15). cART prescribing was in line with national guidelines at the time 
of enrolment. Those not receiving cART in our study had a median CD4+ cell count of 664 
cells/µL, which makes it unlikely that lack of suppression of HIV replication in a minority is 
skewing our findings. Additionally, given the poor concordance of cognitive impairment with 
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other PROMs it seems unlikely excluding a small percentage of our sample would 
dramatically change our results. 
 
Conclusion 
The associations between cognitive impairment and patient-reported measures of physical 
and mental health were weak regardless of the method used to identify those with 
cognitive impairment. However, the cognitive impairment observed was generally mild and 
asymptomatic. Further work is needed to understand the clinical implications of this 
common phenotype in the modern antiretroviral era. 
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